Artelo Biosciences
ARTLArtelo Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that target lipid-signaling modulation pathways, specifically the endocannabinoid system.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
By net margin
Profile
Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that target lipid-signaling modulation pathways, specifically the endocannabinoid system. The company leverages synthetic small molecules and novel crystalline compositions to address significant unmet needs in oncology, pain management, and dermatology. Its core value proposition lies in advancing proprietary and in-licensed assets that modulate biochemical communication systems to treat conditions like cancer-related anorexia and neuropathic pain.
A clinical-stage innovator focused on the endocannabinoid system with a pipeline ranging from pre-clinical to Phase 2a development.
Questions, answered.
- What is Artelo Biosciences's market cap?
- Artelo Biosciences (ARTL) has a market capitalization of $3.5M and trades on NASDAQ.
- Who are Artelo Biosciences's competitors?
- Artelo Biosciences's key competitors include Jazz Pharmaceuticals Inc., Pfizer Inc., Forte Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Artelo Biosciences partner with?
- Artelo Biosciences's notable partners include AstraZeneca plc, adMare Bioinnovations, Stony Brook University, and others.
- Where is Artelo Biosciences headquartered?
- Artelo Biosciences is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2015.